Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GEHC GE HealthCare Technologies	$75.45 +1.4%	$72.74	$57.65 ▼ $94.80	$34.06B	1.14	3.54 million shs	6.40 million shs
PEN Penumbra	$234.24 -0.9%	$260.79	$148.00 ▼ $310.00	$9.16B	0.47	455,539 shs	555,835 shs
SYK Stryker	$390.65 +0.0%	$385.38	$314.93 ▼ $406.19	$149.08B	0.91	1.35 million shs	1.07 million shs
ZBH Zimmer Biomet	$94.20 +0.2%	$93.31	$89.22 ▼ $116.71	$18.60B	0.71	1.82 million shs	1.47 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GEHC GE HealthCare Technologies	+1.42%	-0.08%	+3.55%	+20.97%	-8.70%
PEN Penumbra	-0.93%	-4.02%	-10.13%	-15.32%	+19.03%
SYK Stryker	-0.04%	-0.36%	+3.61%	+12.75%	+17.16%
ZBH Zimmer Biomet	+0.22%	-1.01%	+2.22%	-3.78%	-12.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GEHC GE HealthCare Technologies	4.1374 of 5 stars	3.4	3.0	1.7	0.0	3.5	1.7	2.5
PEN Penumbra	4.7411 of 5 stars	4.4	2.0	0.0	3.7	2.0	2.5	1.9
SYK Stryker	4.4402 of 5 stars	2.4	2.0	3.3	4.2	3.0	2.5	1.3
ZBH Zimmer Biomet	4.9499 of 5 stars	3.2	5.0	2.5	3.7	3.1	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GEHC GE HealthCare Technologies	2.83	Moderate Buy	$88.55	17.36% Upside
PEN Penumbra	2.88	Moderate Buy	$305.07	30.24% Upside
SYK Stryker	2.79	Moderate Buy	$428.55	9.70% Upside
ZBH Zimmer Biomet	2.35	Hold	$111.39	18.25% Upside

Current Analyst Ratings Breakdown

Latest ZBH, PEN, SYK, and GEHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	ZBH Zimmer Biomet	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$135.00
7/14/2025	SYK Stryker	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	GEHC GE HealthCare Technologies	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/9/2025	GEHC GE HealthCare Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$86.00 ➝ $89.00
7/9/2025	PEN Penumbra	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$320.00 ➝ $285.00
7/8/2025	SYK Stryker	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$390.00 ➝ $415.00
7/8/2025	ZBH Zimmer Biomet	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$102.00 ➝ $96.00
5/22/2025	SYK Stryker	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$443.00 ➝ $455.00
5/12/2025	ZBH Zimmer Biomet	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$115.00 ➝ $101.00
5/7/2025	ZBH Zimmer Biomet	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$140.00 ➝ $125.00
5/6/2025	ZBH Zimmer Biomet	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$101.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GEHC GE HealthCare Technologies	$19.67B	1.76	$5.86 per share	12.87	$18.53 per share	4.07
PEN Penumbra	$1.19B	7.59	$2.86 per share	81.90	$29.99 per share	7.81
SYK Stryker	$22.60B	6.60	$15.08 per share	25.90	$54.13 per share	7.22
ZBH Zimmer Biomet	$7.68B	2.43	$13.21 per share	7.13	$62.67 per share	1.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GEHC GE HealthCare Technologies	$1.99B	$4.75	15.88	14.51	2.51	11.02%	24.95%	6.38%	7/30/2025 (Estimated)
PEN Penumbra	$14.01M	$1.06	220.98	46.75	2.11	3.41%	11.14%	8.40%	7/29/2025 (Estimated)
SYK Stryker	$2.99B	$7.40	52.79	26.34	2.95	12.31%	23.74%	11.25%	7/31/2025 (Estimated)
ZBH Zimmer Biomet	$903.70M	$4.52	20.84	10.62	2.17	11.86%	12.73%	7.34%	8/6/2025 (Estimated)

Latest ZBH, PEN, SYK, and GEHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ZBH Zimmer Biomet	$1.99	N/A	N/A	N/A	$2.06 billion	N/A
7/31/2025	Q2 2025	SYK Stryker	$3.06	N/A	N/A	N/A	$5.92 billion	N/A
7/30/2025	Q2 2025	GEHC GE HealthCare Technologies	$0.91	N/A	N/A	N/A	$4.96 billion	N/A
7/29/2025	Q2 2025	PEN Penumbra	$0.81	N/A	N/A	N/A	$327.37 million	N/A
5/5/2025	Q1 2025	ZBH Zimmer Biomet	$1.77	$1.81	+$0.04	$0.91	$1.89 billion	$1.91 billion
5/1/2025	Q1 2025	SYK Stryker	$2.73	$2.84	+$0.11	$1.69	$5.68 billion	$5.87 billion
4/30/2025	Q1 2025	GEHC GE HealthCare Technologies	$0.91	$1.01	+$0.10	$1.23	$4.66 billion	$4.78 billion
4/23/2025	Q1 2025	PEN Penumbra	$0.66	$0.83	+$0.17	$1.00	$315.72 million	$324.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GEHC GE HealthCare Technologies	$0.14	0.19%	N/A	2.95%	1 Years
PEN Penumbra	N/A	N/A	N/A	N/A	N/A
SYK Stryker	$3.36	0.86%	N/A	45.41%	32 Years
ZBH Zimmer Biomet	$0.96	1.02%	N/A	21.24%	N/A

Latest ZBH, PEN, SYK, and GEHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/1/2025	GEHC GE HealthCare Technologies	quarterly	$0.0350	0.19%	7/25/2025	7/25/2025	8/15/2025
5/8/2025	SYK Stryker	quarterly	$0.84	0.88%	6/30/2025	6/30/2025	7/31/2025
5/30/2025	ZBH Zimmer Biomet	quarterly	$0.24	1.03%	6/26/2025	6/26/2025	7/31/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GEHC GE HealthCare Technologies	0.73	0.98	0.76
PEN Penumbra	0.02	6.30	3.68
SYK Stryker	0.69	1.64	1.00
ZBH Zimmer Biomet	0.53	2.44	1.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GEHC GE HealthCare Technologies	82.06%
PEN Penumbra	88.88%
SYK Stryker	77.09%
ZBH Zimmer Biomet	88.89%

Insider Ownership

Company	Insider Ownership
GEHC GE HealthCare Technologies	0.28%
PEN Penumbra	4.20%
SYK Stryker	5.90%
ZBH Zimmer Biomet	1.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GEHC GE HealthCare Technologies	53,000	457.89 million	456.60 million	Optionable
PEN Penumbra	4,500	38.73 million	37.10 million	Optionable
SYK Stryker	53,000	381.69 million	359.17 million	Optionable
ZBH Zimmer Biomet	17,000	197.85 million	195.10 million	Optionable

ZBH, PEN, SYK, and GEHC Headlines

Recent News About These Companies

MONOGRAM TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Monogram Technologies Inc. - MGRM

July 16 at 11:36 AM | businesswire.com

Needham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH)

July 16 at 10:43 AM | insidermonkey.com

Equity Investment Corp Acquires 17,286 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 16 at 8:45 AM | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Zimmer Biomet Holdings (ZBH) and Eli Lilly & Co (LLY)

July 16 at 6:08 AM | theglobeandmail.com

New York State Common Retirement Fund Grows Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 16 at 4:33 AM | marketbeat.com

Zimmer Biomet enters agreement to acquire orthopaedic robotics company, Monogram Technologies

July 15 at 12:15 AM | pharmabiz.comP

Zimmer Biomet inks $177M deal for Monogram and its hands-free orthopedic robot

July 15 at 7:13 PM | fiercebiotech.comF

Zimmer Biomet wins price target raise at Roth

July 15 at 7:13 PM | cantechletter.comC

Zimmer upgraded to Buy at Roth Capital on Monogram deal

July 15 at 7:13 PM | msn.com

Bryn Mawr Capital Management LLC Boosts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 15 at 9:40 AM | marketbeat.com

Zimmer Biomet (NYSE:ZBH) Raised to Buy at Roth Capital

July 15 at 8:43 AM | marketbeat.com

Zimmer to acquire Monogram Technologies for $177 million, boosting robotics portfolio

July 14 at 12:19 AM | msn.com

Zimmer Biomet acquisition of Monogram Technologies to expand capacity in robotics devices

July 14 at 12:19 AM | journalgazette.netJ

Zimmer Biomet to acquire Monogram Technologies for $177M

July 14 at 12:19 AM | therobotreport.comT

Monogram Technologies Shares Surge After Zimmer Biomet Announces Acquisition

July 14 at 12:19 AM | msn.com

Envestnet Asset Management Inc. Purchases 66,114 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 14 at 4:02 AM | marketbeat.com

Canaccord Genuity Reaffirms Their Hold Rating on Zimmer Biomet Holdings (ZBH)

July 13, 2025 | theglobeandmail.com

Speece Thorson Capital Group Inc. Has $20.23 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 13, 2025 | marketbeat.com

Citi Remains a Hold on Zimmer Biomet Holdings (ZBH)

July 11, 2025 | theglobeandmail.com

Country Club Bank Buys Shares of 35,777 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

July 11, 2025 | marketbeat.com

Getinge, Zimmer Biomet Announce Partnership In The ASC Sector

July 10, 2025 | inkfreenews.comI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
By Jeffrey Neal Johnson | June 18, 2025
View Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom

ZBH, PEN, SYK, and GEHC Company Descriptions

GE HealthCare Technologies NASDAQ:GEHC

$75.45 +1.06 (+1.42%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$75.22 -0.23 (-0.30%)

As of 07:20 AM Eastern

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Penumbra NYSE:PEN

$234.24 -2.17 (-0.92%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$232.35 -1.89 (-0.81%)

As of 07/16/2025 05:44 PM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Stryker NYSE:SYK

$390.65 +0.06 (+0.01%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$390.75 +0.10 (+0.03%)

As of 07/16/2025 06:11 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Zimmer Biomet NYSE:ZBH

$94.20 +0.17 (+0.18%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$94.17 -0.02 (-0.02%)

As of 07:00 AM Eastern

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time